Carbapenem antibiotics are important medicines used to treat serious bacterial infections. However, increasing carbapenem resistance has become a major concern, particularly among Gram-negative bacteria.
One important cause of this resistance is the production of carbapenemases, enzymes that can break down carbapenem antibiotics.
Some carbapenemases belong to the metallo-beta-lactamase family, making MBL resistance an important part of the broader antimicrobial resistance discussion.
Understanding these resistance mechanisms can help explain why newer antibiotic combinations and beta-lactamase inhibitors are being developed.
What Is Carbapenem Resistance?
Carbapenem resistance occurs when bacteria are no longer effectively inhibited by carbapenem antibiotics.
Bacteria can develop or acquire resistance through several mechanisms, including:
- Production of carbapenemase enzymes
- Changes in bacterial membrane permeability
- Increased efflux of antibiotics
- Changes in antibiotic targets
- Combination of multiple resistance mechanisms
Among these, carbapenemase production is particularly important because these enzymes can directly destroy susceptible beta-lactam antibiotics.
What Are Carbapenemases?
Carbapenemases are beta-lactamase enzymes capable of hydrolyzing carbapenem antibiotics.
They belong to different molecular classes and do not all have the same characteristics.
Some clinically important carbapenemases include KPC, NDM, VIM, IMP and OXA-type enzymes.
The specific enzyme produced by a bacterial isolate can influence its resistance profile and the antimicrobial options that may remain active.
MBL Resistance and Carbapenems
Metallo-beta-lactamases, or MBLs, are particularly important carbapenemases.
Examples include:
- NDM
- VIM
- IMP
These enzymes require metal ions for their activity and can hydrolyze many beta-lactam antibiotics.
A major challenge is that commonly used beta-lactamase inhibitors, including Avibactam, do not directly inhibit MBLs.
This makes infections involving MBL-producing bacteria particularly challenging.
What Role Does Avibactam Play?
Avibactam is a beta-lactamase inhibitor with activity against several serine beta-lactamases.
It can protect a partner beta-lactam antibiotic from susceptible beta-lactamase enzymes.
However, it is important to understand that Avibactam does not directly inhibit MBLs.
Its role becomes particularly interesting when bacteria produce multiple beta-lactamases.
For example, an MBL-producing organism may also produce another beta-lactamase that can inactivate aztreonam.
In this situation, Avibactam can inhibit susceptible accompanying beta-lactamases.
Aztreonam Avibactam and Complex Resistance
The complementary activity of aztreonam and Avibactam is one reason Aztreonam Avibactam has become an important topic in antimicrobial resistance research.
Aztreonam is relatively stable against MBL-mediated hydrolysis.
At the same time, other beta-lactamases produced by the same organism may be able to degrade aztreonam.
Avibactam can inhibit several of these susceptible enzymes.
Therefore, the combination can address different parts of a complex resistance mechanism.
Why Is Carbapenem Resistance Difficult to Manage?
Carbapenem-resistant bacteria may carry more than one resistance mechanism.
A single bacterial isolate can potentially produce multiple beta-lactamases while also showing changes in permeability or antibiotic efflux.
This makes laboratory testing particularly important.
Identifying the organism, determining antimicrobial susceptibility and, where appropriate, understanding the underlying resistance mechanism can help inform treatment decisions.
Importance of Beta-Lactamase Inhibitors
Beta-lactamase inhibitors provide one strategy for overcoming resistance caused by susceptible beta-lactamases.
Different inhibitors have different activity profiles, so they cannot be considered interchangeable.
Avibactam, for example, has activity against several serine beta-lactamases but not MBLs.
Understanding these differences is important when discussing antibiotic combinations and resistance mechanisms.
Conclusion
Carbapenem resistance is a complex problem, particularly when caused by carbapenemase-producing Gram-negative bacteria.
MBLs such as NDM, VIM and IMP can contribute significantly to resistance, while bacteria may also carry additional beta-lactamases and other resistance mechanisms.
Although Avibactam does not directly inhibit MBLs, its activity against several serine beta-lactamases can provide complementary protection when used with an appropriate antibacterial agent.
The Aztreonam Avibactam combination illustrates how understanding individual resistance mechanisms can help guide the development of targeted antimicrobial strategies.
As antimicrobial resistance continues to evolve, mechanism-based approaches will remain an important area of research and clinical interest.
Medical note: This article is for educational purposes only. Antibiotic treatment should be determined by qualified healthcare professionals based on microbiological testing, patient factors and applicable clinical guidelines.